重庆医学
重慶醫學
중경의학
Chongqing Medicine
2015年
29期
4095-4097,4101
,共4页
赵昌东%张小节%张磊%罗红波%陈娴%张辉%张一峰
趙昌東%張小節%張磊%囉紅波%陳嫻%張輝%張一峰
조창동%장소절%장뢰%라홍파%진한%장휘%장일봉
结肠炎 ,溃疡性%肠黏膜%参芪扶正注射液%CX3CR1
結腸炎 ,潰瘍性%腸黏膜%參芪扶正註射液%CX3CR1
결장염 ,궤양성%장점막%삼기부정주사액%CX3CR1
colitis,ulcerative%intestinal mucosa%shenqifuzheng injection%CX3CR1
目的:观察参芪扶正注射液联合柳氮磺吡啶(SASP)治疗溃疡性结肠炎(UC)的临床治疗效果,并探讨参芪扶正注射液对UC患者大肠黏膜CX3CR1的影响。方法选择2012年1月至2014年6月在该院就诊的轻中度活动期UC患者50例,将其分为观察组、对照组,另设健康组15例,观察组予以参芪扶正注射液联合SASP治疗,对照组予以SASP治疗,健康组为空白对照。观察所有UC患者治疗前和治疗2周后的改良Mayo评分结果,并观察健康组及观察组、对照组患者治疗前和治疗后2周同一病变部位大肠黏膜CX3CR1的表达情况。结果 UC患者治疗前大肠黏膜CX3CR1总阳性率为88.37%,健康组大肠黏膜CX3CR1总阳性率为20.00%,两者比较差异有统计学意义(Z=-2.689,P<0.01);治疗后2周,观察组大肠黏膜CX3CR1的表达和改良 Mayo 评分结果均明显低于对照组(P<0.05);观察组临床综合疗效明显优于对照组(Z=-2.085,P<0.05)。结论参芪扶正注射液联合SASP治疗UC疗效明显优于单纯口服SASP ,参芪扶正注射液可能通过抑制大肠黏膜CX3CR1的表达而参与了UC的治疗。
目的:觀察參芪扶正註射液聯閤柳氮磺吡啶(SASP)治療潰瘍性結腸炎(UC)的臨床治療效果,併探討參芪扶正註射液對UC患者大腸黏膜CX3CR1的影響。方法選擇2012年1月至2014年6月在該院就診的輕中度活動期UC患者50例,將其分為觀察組、對照組,另設健康組15例,觀察組予以參芪扶正註射液聯閤SASP治療,對照組予以SASP治療,健康組為空白對照。觀察所有UC患者治療前和治療2週後的改良Mayo評分結果,併觀察健康組及觀察組、對照組患者治療前和治療後2週同一病變部位大腸黏膜CX3CR1的錶達情況。結果 UC患者治療前大腸黏膜CX3CR1總暘性率為88.37%,健康組大腸黏膜CX3CR1總暘性率為20.00%,兩者比較差異有統計學意義(Z=-2.689,P<0.01);治療後2週,觀察組大腸黏膜CX3CR1的錶達和改良 Mayo 評分結果均明顯低于對照組(P<0.05);觀察組臨床綜閤療效明顯優于對照組(Z=-2.085,P<0.05)。結論參芪扶正註射液聯閤SASP治療UC療效明顯優于單純口服SASP ,參芪扶正註射液可能通過抑製大腸黏膜CX3CR1的錶達而參與瞭UC的治療。
목적:관찰삼기부정주사액연합류담광필정(SASP)치료궤양성결장염(UC)적림상치료효과,병탐토삼기부정주사액대UC환자대장점막CX3CR1적영향。방법선택2012년1월지2014년6월재해원취진적경중도활동기UC환자50례,장기분위관찰조、대조조,령설건강조15례,관찰조여이삼기부정주사액연합SASP치료,대조조여이SASP치료,건강조위공백대조。관찰소유UC환자치료전화치료2주후적개량Mayo평분결과,병관찰건강조급관찰조、대조조환자치료전화치료후2주동일병변부위대장점막CX3CR1적표체정황。결과 UC환자치료전대장점막CX3CR1총양성솔위88.37%,건강조대장점막CX3CR1총양성솔위20.00%,량자비교차이유통계학의의(Z=-2.689,P<0.01);치료후2주,관찰조대장점막CX3CR1적표체화개량 Mayo 평분결과균명현저우대조조(P<0.05);관찰조림상종합료효명현우우대조조(Z=-2.085,P<0.05)。결론삼기부정주사액연합SASP치료UC료효명현우우단순구복SASP ,삼기부정주사액가능통과억제대장점막CX3CR1적표체이삼여료UC적치료。
Objective To observe the clinical efficacy of shenqifuzheng injection combined with sulfasalazine (SASP) in the treatment of ulcerative colitis (UC) ,and to evaluate the effect of CX3CR1 on colonic mucosa of UC in treatment with shenqifuzheng injection .Methods Fifty‐one patients with active mild to moderate UC were collected during the period from January 2012 to June 2014 in the second people′s hospital of Lianyungang ,which randomly divided into experimental group and control group ,and setting up health group of 15 cases .Experimental group were treated with shenqifuzheng injection combined with SASP ,control group were only with SASP ,health group were no‐treatment control .The modified Mayo scoring results and the expression of CX3CR1 on co‐lonic mucosa of the same lesion site were observed before and two weeks after treatment separately .Results The total positive rate of CX3CR1 on colonic mucosa in patients with ulcerative colitis was 88 .37% before treatment ,The total positive rate of CX3CR1 on colonic mucosa in health group was 20 .00% ,There was significant difference between two groups (Z= -2 .689 ,P<0 .01) .Two weeks after treatment ,the expression of CX3CR1 on colonic mucosa and the modified Mayo scoring results in the experimental group were significantly lower than those in the control group (P<0 .05) .The clinical comprehensive efficacy of the experimental group was significantly better than the control group (Z= -2 .085 ,P<0 .05) .Conclusion Combination of shenqifuzheng injection and SASP is more effective than using SASP alone in the treatment of UC .Shenqifuzheng injection may play important role in the treatment of UC by inhibiting the expression of CX3CR1 on colonic mucosa .